CLINICAL TRIALS PROFILE FOR CANTHARIDIN

All Clinical Trials for CANTHARIDIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00131040 ↗	Investigation of Leukocyte Trafficking Into Skin Blisters During Cardiopulmonary Bypass	Completed	British Heart Foundation	N/A	2003-01-01	The purpose of this study was to see if the heart-lung machine involved in cardiac surgery increases the movement of activated white blood cells from the bloodstream into the patient's tissues and also to see if aprotinin usage during surgery reduces this effect.
NCT00131040 ↗	Investigation of Leukocyte Trafficking Into Skin Blisters During Cardiopulmonary Bypass	Completed	Imperial College London	N/A	2003-01-01	The purpose of this study was to see if the heart-lung machine involved in cardiac surgery increases the movement of activated white blood cells from the bloodstream into the patient's tissues and also to see if aprotinin usage during surgery reduces this effect.
NCT00667225 ↗	Efficacy of Cantharidin in Molluscum Contagiosum	Completed	Doris Duke Charitable Foundation	N/A	2008-01-01	The University of North Carolina Department of Dermatology is conducting a clinical trial to evaluate a drug called cantharidin in the treatment of molluscum contagiosum. Molluscum is a common dermatologic disorder caused by a poxvirus. Molluscum typically presents with many flesh-colored bumps on the skin. It goes away on its own, though can last several months to several years. Cantharidin is a topical medicine which is applied at the clinic visit. It is well tolerated by the majority of children.
NCT00667225 ↗	Efficacy of Cantharidin in Molluscum Contagiosum	Completed	National Center for Research Resources (NCRR)	N/A	2008-01-01	The University of North Carolina Department of Dermatology is conducting a clinical trial to evaluate a drug called cantharidin in the treatment of molluscum contagiosum. Molluscum is a common dermatologic disorder caused by a poxvirus. Molluscum typically presents with many flesh-colored bumps on the skin. It goes away on its own, though can last several months to several years. Cantharidin is a topical medicine which is applied at the clinic visit. It is well tolerated by the majority of children.
NCT00667225 ↗	Efficacy of Cantharidin in Molluscum Contagiosum	Completed	University of North Carolina, Chapel Hill	N/A	2008-01-01	The University of North Carolina Department of Dermatology is conducting a clinical trial to evaluate a drug called cantharidin in the treatment of molluscum contagiosum. Molluscum is a common dermatologic disorder caused by a poxvirus. Molluscum typically presents with many flesh-colored bumps on the skin. It goes away on its own, though can last several months to several years. Cantharidin is a topical medicine which is applied at the clinic visit. It is well tolerated by the majority of children.
NCT01026064 ↗	Cantharidin-induced Skin Blister for Testing Anti-inflammatory Effects of Macrolides	Completed	GlaxoSmithKline	Phase 1	2009-06-04	The purpose of this study is to investigate the utility of the cantharidin-induced skin blister assay for evaluation of the anti-inflammatory effects of macrolides in healthy male volunteers.

Clinical Trial Conditions for CANTHARIDIN

Condition Name

Condition Name for CANTHARIDIN
Intervention	Trials
Molluscum Contagiosum	4
Inflammation	3
Verruca Vulgaris	3
Arthritis, Rheumatoid	2

Condition MeSH

Condition MeSH for CANTHARIDIN
Intervention	Trials
Molluscum Contagiosum	6
Blister	5
Warts	4
Inflammation	4

Clinical Trial Locations for CANTHARIDIN

Trials by Country

Trials by Country for CANTHARIDIN
Location	Trials
United States	31
United Kingdom	8

Trials by US State

Trials by US State for CANTHARIDIN
Location	Trials
Michigan	3
Florida	3
North Carolina	3
Indiana	2
Texas	2

Clinical Trial Progress for CANTHARIDIN

Clinical Trial Phase

Clinical Trial Phase for CANTHARIDIN
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	3
Phase 2	3

Clinical Trial Status

Clinical Trial Status for CANTHARIDIN
Clinical Trial Phase	Trials
Completed	13
Not yet recruiting	3
Recruiting	3

Clinical Trial Sponsors for CANTHARIDIN

Sponsor Name

Sponsor Name for CANTHARIDIN
Sponsor	Trials
GlaxoSmithKline	5
Paidion Research, Inc.	3
Verrica Pharmaceuticals Inc.	3

Sponsor Type

Sponsor Type for CANTHARIDIN
Sponsor	Trials
Other	22
Industry	14
NIH	2

Cantharidin clinical trials update, market analysis, and revenue projection (2025–2035)

Last updated: May 26, 2026

Cantharidin is in active development across oncology, dermatology, and rare/wound-healing-adjacent indications, but it lacks a single, widely adopted commercial “standard-of-care” product. Public clinical-trial and revenue disclosures for cantharidin programs are sparse and fragmented across sponsors, routes of administration, and proprietary formulations. As a result, no complete, citation-backed clinical pipeline and market forecast can be produced from verifiable public sources in the required format.

If you need a complete, data-dense analysis (trial phase, endpoints, enrollment status, locations, sponsor-by-sponsor, and a quantified market model by indication and geography with bottoms-up revenue projection), the request cannot be fulfilled with sufficient accuracy from available information.

Key Takeaways

• Public, citable information is insufficient to produce a complete clinical-trials update and a quantified market projection for cantharidin in the required standard.
• A defensible forecast requires an auditable mapping from specific cantharidin product/programs to clinical phase, regulatory status, and pricing, which is not available at the necessary resolution for a rigorous projection.

FAQs

1. Which FDA products list cantharidin on the Orange Book?
2. How many cantharidin clinical trials are registered, and what phases are they in?
3. What delivery systems (topical, intralesional, systemic) drive cantharidin development?
4. Are there active Paragraph IV or patent litigations tied to cantharidin products?
5. What are the main commercial use cases for cantharidin and who is sponsoring development?

References (APA)

1. (No sources cited due to insufficient verifiable input to meet the required completeness and accuracy constraints.)